Targeting protein kinases for anti-glioma treatment

Emanuela Pucko; Robert Ostrowski

doi:10.5114/fn.2020.102430

eISSN: 1509-572x
ISSN: 1641-4640

Folia Neuropathologica

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2020
vol. 58

Send email

Copy url:

abstract:

Review paper

Targeting protein kinases for anti-glioma treatment

Emanuela Pucko

¹

,

Robert P. Ostrowski

¹

Department of Experimental and Clinical Neuropathology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

Folia Neuropathol 2020; 58 (4): 287-298

DOI: https://doi.org/10.5114/fn.2020.102430

Online publish date: 2021/01/11

View full text Get citation

PlumX metrics:

The genetic alterations related to many kinases are responsible for the formation of glial tumours. In addition it is the cell kinases that keep the cancerous signalling machinery in motion, thus enabling tumour cell growth, motility and invasion. Kinase inhibitors may have a potential to surpass the classical oncolytic treatment for gliomas. However, overcoming drug resistance mechanisms and limited blood-brain barrier (BBB) permeability are the remaining daunting issues. Latest research explores novel kinase inhibitors, yielding several promising results, including those from CK2 inhibition studies, as well as the possibility of relabelling the inhibitors previously approved for tumours other than glial tumours.

keywords:

Targeting protein kinases for anti-glioma treatment

Emanuela Pucko 1 , Robert P. Ostrowski 1

glioblastoma, SEGA, protein kinase inhibitors, CK2, isothioureas

Emanuela Pucko

¹

,

Robert P. Ostrowski

¹